Summary: In a busy August, the FDA approved seven new investigational drugsfor the marketplace,twice the monthly average of approvals for the first half of 2019. Four drugs in the Pharmaceutical Pipeline Tracker received new FDA Priority Designations. Two drugs hit bumps in the road with one rejection and one PDUFA Date delay. Seven drugs were involved with new NDA and BLA submissions. Finally, we’ve included two notable other developments. Read on.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right